Edwards Lifesciences Corporation (EW)

Market Cap	49.38B +19.0%
Revenue (ttm)	6.07B +11.5%
Net Income	1.07B -74.3%
EPS	1.83 -73.7%
Shares Out	580.30M
PE Ratio	45.50
Forward PE	28.20
Dividend	n/a
Ex-Dividend Date	n/a

Volume	301,617
Open	83.97
Previous Close	83.40
Day's Range	83.97 - 85.24
52-Week Range	65.94 - 87.89
Beta	0.94
Analysts	Buy
Price Target	96.47 (+13.36%)
Earnings Date	Feb 10, 2026

About EW

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. It also provides surgical structural heart solution...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Mar 27, 2000
• Employees: 15,800
• Stock Exchange: NYSE
• Ticker Symbol: EW
• Website: https://www.edwards.com

Financial Performance

In 2025, Edwards Lifesciences's revenue was $6.07 billion, an increase of 11.55% compared to the previous year's $5.44 billion. Earnings were $1.07 billion, a decrease of -74.28%.

Analyst Summary

According to 21 analysts, the average rating for EW stock is "Buy." The 12-month stock price target is $96.47, which is an increase of 13.36% from the latest price.

Price Target

$96.47

(13.36% upside)

Analyst Consensus: Buy